Alvimopan Patent Expiration

Alvimopan is Used for accelerating gastrointestinal recovery following bowel resection surgeries. It was first introduced by Cubist Pharmaceuticals Inc in its drug Entereg on May 20, 2008. 4 different companies have introduced drugs containing Alvimopan.


Alvimopan Patents

Given below is the list of patents protecting Alvimopan, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Entereg US8112290 Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug Jul 31, 2030 Cubist Pharms
Entereg US8946262 Methods of preventing and treating gastrointestinal dysfunction Feb 12, 2030 Cubist Pharms
Entereg US8645160 Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug Jun 18, 2029 Cubist Pharms
Entereg US6469030 Methods for the treatment and prevention of ileus Nov 29, 2020

(Expired)

Cubist Pharms
Entereg US5250542 Peripherally selective piperidine carboxylate opioid antagonists Mar 29, 2016

(Expired)

Cubist Pharms
Entereg US5434171 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates Dec 08, 2013

(Expired)

Cubist Pharms



Alvimopan's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Alvimopan Generic API Manufacturers

Several generic applications have been filed for Alvimopan. The first generic version for Alvimopan was by Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc and was approved on Dec 19, 2019. And the latest generic version is by Hikma Pharmaceuticals Usa Inc and was approved on Aug 31, 2023.

Given below is the list of companies who have filed for Alvimopan generic, along with the locations of their manufacturing plants worldwide.


1. ENDO OPERATIONS

Endo Operations Ltd has filed for 1 generic for Alvimopan. Given below are the details of the strengths of this generic introduced by Endo Operations.

Strength Dosage Form Availability Application Pathway TE code Launch Date
12MG

capsule Prescription ORAL AB Jan 24, 2023





2. HIKMA

Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Alvimopan. Given below are the details of the strengths of this generic introduced by Hikma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
12MG

capsule Prescription ORAL AB Aug 31, 2023


Manufacturing Plant Locations
New

Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.

Country City Firm Name
United States
Eatontown Hikma Pharmaceuticals USA, Inc.
Cherry Hill Hikma Pharmaceuticals USA Inc.
Dayton Hikma Injectables USA Inc
Carlsbad Hikma Cali Inc. DBA Leucadia Pharmaceuticals
Portugal
Terrugem Snt Hikma Farmaceutica, (Portugal) S.A.
Jordan
Amman Hikma Pharmaceuticals LLC





3. WATSON LABS TEVA

Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 1 generic for Alvimopan. Given below are the details of the strengths of this generic introduced by Watson Labs Teva.

Strength Dosage Form Availability Application Pathway TE code Launch Date
12MG

(reference standard)

capsule Prescription ORAL AB Dec 19, 2019